Core Viewpoint - AngioDynamics (ANGO) has experienced a significant decline of 25% over the past four weeks, but it is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1]. Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - ANGO's current RSI reading is 22.62, suggesting that the heavy selling pressure may be exhausting, indicating a possible bounce back towards equilibrium in supply and demand [5]. Fundamental Analysis - There is a strong consensus among sell-side analysts that earnings estimates for ANGO have increased by 3.6% over the last 30 days, which typically correlates with price appreciation in the near term [7]. - ANGO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

Core Insights - AngioDynamics, Inc. (ANGO) reported breakeven adjusted earnings per share for the second quarter of fiscal 2026, an improvement from a loss of 4 cents in the same quarter last year, surpassing the Zacks Consensus Estimate of a loss of 10 cents [1][2] - The company’s pro-forma revenues for the fiscal second quarter reached $79.4 million, reflecting an 8.8% year-over-year increase and exceeding the Zacks Consensus Estimate by 4.5% [3][10] - Despite the positive financial results, shares of AngioDynamics fell nearly 13.5% in the trading session following the announcement [4] Revenue Analysis - U.S. net revenues for the quarter totaled $67.6 million, up 7.8% year over year, surpassing the estimate of $62.3 million [5] - Pro-forma international revenues were $11.8 million, an 8.8% increase from the previous year, exceeding the projection of $10.2 million [5] Segment Performance - The Med Tech segment reported pro-forma net sales of $35.7 million, a 13% increase year over year, outperforming the estimate of $32.7 million [6] - Key drivers included Auryon sales of $16.3 million (up 18.6% year over year) and Mechanical Thrombectomy revenues of $11 million (up 3.9% year over year) [7] - Pro-forma Med Device revenues totaled $43.8 million, reflecting a 5.6% increase compared to the previous year, also exceeding the estimate of $39.9 million [8] Margin and Expense Analysis - AngioDynamics' pro forma gross profit rose 14% to $44.8 million, with gross margin expanding by 170 basis points to 56.4%, surpassing the projected margin of 54.2% [11][10] - Sales and marketing expenses increased by 4.4% year over year to $26.7 million, while R&D expenses rose by 20.7% to $7.8 million [12] Cash Position - The company ended the second quarter with cash and cash equivalents of $41.6 million, up from $38.8 million at the end of the previous quarter, with no debt on its balance sheet [13] Fiscal Year Guidance - AngioDynamics updated its fiscal 2026 sales guidance to a range of $312-$314 million, up from the previous guidance of $308-$313 million [14] - The company anticipates Med Tech revenue growth of 14-16% and flat to 1% growth for Med Device revenues [15] - Adjusted loss per share is projected to be between 33 cents and 23 cents, with the Zacks Consensus Estimate at a loss of 28 cents per share [16] Overall Assessment - AngioDynamics demonstrated strong execution in the second quarter, with revenue growth driven by the higher-margin Med Tech portfolio, which now accounts for 45% of total revenue [17] - Auryon continues to be a significant growth driver, achieving its 18th consecutive quarter of double-digit growth [18] - The Mechanical Thrombectomy segment showed mid-single-digit growth, with regulatory advancements expected to enhance adoption and clinical use [19]

Core Insights - AngioDynamics reported a Q2 2026 EPS of -$0.15, missing the estimated -$0.10, but exceeded revenue expectations with $79.43 million compared to the estimated $76.7 million [1][6] - The company experienced double-digit growth in its medical technology segment, contributing to increased profitability despite a negative P/E ratio of approximately -14.67 [2][6] - AngioDynamics raised its fiscal year 2026 adjusted EPS guidance, indicating a positive outlook for future performance, although shares declined by 1.8% to close at $12.87 [4][6] Financial Performance - Analysts had forecasted a quarterly loss of 10 cents per share, which is deeper than the 4 cents per share loss from the same quarter last year [3] - Revenue of $79.43 million surpassed the previous year's $72.84 million, indicating a positive trend in sales [3] - The company's price-to-sales ratio of about 1.56 suggests that investors are paying $1.56 for every dollar of sales, reflecting confidence in its revenue-generating capabilities [3] Analyst Sentiment - Canaccord Genuity analyst William Plovanic maintained a Buy rating and increased the price target from $17 to $18, indicating positive sentiment from analysts regarding the company's potential [4] - Despite financial challenges, the company maintains a strong current ratio of about 2.29, suggesting solid ability to cover short-term liabilities with short-term assets [5]

Financial Performance - Net sales for the three months ended November 30, 2025, increased by $6.6 million to $79.4 million, compared to $72.8 million in the same period of the prior year, representing an increase of 9.0%[111] - The Company reported a net loss of $6.4 million for the three months ended November 30, 2025, a decrease of $4.4 million compared to a net loss of $10.7 million in the same quarter of the prior year[109] - For the six months ended November 30, 2025, net sales increased by $14.8 million to $155.1 million, compared to $140.3 million in the same period of the prior year, representing an increase of 10.6%[111] - The company reported a net loss of $17.3 million and $23.5 million for the six months ended November 30, 2025 and 2024, respectively[131] Revenue Growth - Med Tech revenue grew by 13.0% in the second quarter of fiscal year 2026, driven by Auryon, NanoKnife, and thrombus management products[108] - The Company’s Med Device revenue grew by 6.0% in the second quarter of fiscal year 2026, driven by growth in Core, Ports, and Venous product lines[108] - Increased sales of Auryon contributed $2.6 million and $5.3 million for the three and six months ended November 30, 2025, respectively[114] Margins - Gross margin increased by 160 basis points to 56.4% for the three months ended November 30, 2025, compared to 54.8% in the same period of the prior year[111] - Med Tech gross margin increased to 65.3% for the three months ended November 30, 2025, up from 63.7% in the same period of the prior year[115] - The Med Device segment gross margin increased by $1.7 million and $2.6 million for the three and six months ended November 30, 2025, compared to the same period in the prior year[117] Expenses - Research and development (R&D) expense increased by $1.3 million and $1.5 million for the three and six months ended November 30, 2025, respectively[120] - Selling and marketing (S&M) expense rose by $1.1 million and $3.6 million for the three and six months ended November 30, 2025, respectively[121] - General and administrative (G&A) expense decreased by $0.2 million for the three months but increased by $1.3 million for the six months ended November 30, 2025[122] Cash and Debt Position - Cash and cash equivalents totaled $41.6 million as of November 30, 2025, down from $55.9 million as of May 31, 2025[128] - Cash used in operating activities was $11.3 million and $15.8 million for the six months ended November 30, 2025 and 2024, respectively[131] - As of November 30, 2025, the Company had no outstanding debt, indicating a strong financial position[137] - The Company has a $25.0 million secured revolving credit facility with interest rates based on SOFR plus 0.1% or an alternate base rate, with no amounts outstanding as of November 30, 2025[138] Risk Management - Approximately 4.6% of the company's sales for the six months ended November 30, 2025, were denominated in foreign currencies, exposing profitability to currency fluctuations[136] - The Company mitigates credit risk by maintaining cash and cash equivalents at various institutions and regularly evaluating their credit standings[139] - No single customer accounts for more than 10% of total sales, reducing concentration of credit risk in trade accounts receivable[140] - The standard payment terms for customers are 30 to 90 days from invoicing, minimizing significant financing provided to customers[140] - The Company does not foresee significant credit risk associated with outstanding accounts receivable, relying on the financial stability of its customers[140] Future Outlook - The Company expects to grow by expanding geographically, penetrating new markets, and introducing new products[106] - The backlog at November 30, 2025, was $0.4 million, primarily impacting sales of Core products[112] - Acquisition, restructuring, and other items, net, decreased by $2.2 million and $3.8 million for the three and six months ended November 30, 2025, respectively[125] - The effective tax rate for the three months ended November 30, 2025, was 0.1%, compared to 1.0% for the same period in the prior year[127]

Core Insights - AngioDynamics reported a strong performance in the first quarter of fiscal year 2026, with a revenue increase of 12.2% to $75.7 million, driven by growth in both Med Tech and Med Device segments [15][4][5] - The Med Tech segment saw significant growth of 26.1%, while the Med Device segment grew by 2.3% [15][16] - The company is focused on strategic transformation, emphasizing profitability alongside revenue growth, and plans to continue investing in product development and regulatory opportunities [4][5][28] Financial Performance - Total revenue for Q1 FY 2026 was $75.7 million, a 12.2% increase compared to the same quarter in FY 2025 [15] - Med Tech revenue reached $35.3 million, reflecting a 26.1% year-over-year growth, while Med Device revenue was $40.4 million, up 2.3% [15][16] - Gross margin improved to 55.3%, a 90-basis-point increase from the previous year, driven by pricing initiatives and a favorable sales mix [19][20] Segment Highlights - The Auryon platform generated $16.5 million in revenue, growing 20.1% year-over-year, marking 17 consecutive quarters of double-digit growth [17] - Mechanical Thrombectomy revenue, including AngioVac and AlphaVac, increased by 41.2% year-over-year, totaling $11.3 million [18] - NanoKnife revenue was $6.4 million, a 26.7% increase, with expectations for continued growth driven by increased adoption in prostate cancer treatment [10][18] Strategic Initiatives - The company is expanding its sales force for Mechanical Thrombectomy, increasing dedicated sales representatives from 40 to 50 to support growth [39] - AngioDynamics is focused on enhancing its product portfolio and market penetration, particularly in the hospital sector, to drive future growth [6][9] - The company plans to maintain a strong emphasis on research and development, targeting approximately 10% of sales for R&D initiatives [21] Guidance and Outlook - AngioDynamics raised its fiscal year 2026 net sales guidance to a range of $308 million to $313 million, reflecting growth of 5% to 7% over the previous year [24][25] - The company expects Med Tech net sales to grow 14% to 16%, while Med Device sales are anticipated to remain flat [26] - Adjusted EBITDA is projected to be between $6 million and $10 million, an increase from prior guidance [27]

Core Insights - AngioDynamics reported strong financial performance for the third quarter of fiscal year 2025, with total worldwide revenue reaching $72 million, reflecting a year-over-year growth of over 9% [5][18]. - The company has increased its guidance for total revenue, MedTech growth, gross margin, adjusted EBITDA, and adjusted EPS for the fiscal year 2025, indicating confidence in its operational strategy and market position [6][30]. Financial Performance - Total revenue for the third quarter was $72 million, with MedTech segment revenue growing by 22% to $31.3 million, while the Med Device segment saw a slight increase of 0.9% to $40.7 million [5][18]. - Adjusted EBITDA was reported at $1.3 million, a significant improvement from a loss of $3.6 million in the prior year [25]. - The adjusted net loss was $3.1 million, or an adjusted loss per share of $0.08, improving from a loss of $6.5 million or $0.16 per share in the same quarter last year [24]. Product Performance - The Auryon platform generated $13.9 million in revenue, growing 17.3% year-over-year, marking 15 consecutive quarters of double-digit growth [18]. - Mechanical Thrombectomy revenue, including AlphaVac and AngioVac, increased by 46.7% year-over-year, with AlphaVac revenue soaring by 161.4% [19]. - NanoKnife revenue reached $6.3 million, a 5.3% increase, with disposable revenue growing by 16.2% [19]. Strategic Outlook - The company expects revenue for fiscal 2025 to be in the range of $285 million to $288 million, representing growth of 5.3% to 6.4% over fiscal year 2024 [29]. - MedTech net sales are projected to grow between 14% to 16%, while Med Device net sales are expected to remain flat [30]. - The company is focused on increasing penetration in the hospital market for Auryon and expanding its sales force for AlphaVac and AngioVac to drive further growth [32][47]. Research and Development - R&D expenses were $6.9 million, or 9.6% of sales, down from $8.1 million or 12.2% of sales a year ago, reflecting a commitment to long-term growth in the MedTech segment [23]. - The AMBITION BTK trial is set to evaluate clinical outcomes for Auryon, with enrollment expected to begin in the next quarter [53]. Market Position - The company is well-positioned with a strong balance sheet, reporting $44.8 million in cash and cash equivalents as of February 28, 2025 [25]. - AngioDynamics is focused on driving sustainable, profitable growth through its innovative product portfolio and strategic market initiatives [35][58].

Core Insights - AngioDynamics reported a solid first quarter for fiscal year 2025, with total worldwide revenue of $67.5 million, reflecting a year-over-year growth of just over 1% [5][18] - The MedTech segment showed strong performance, growing approximately 9%, driven by products like Auryon and AlphaVac, which both experienced growth exceeding 20% [5][6] - The company is focused on achieving profitability, reporting an adjusted EBITDA loss of $200,000, a significant improvement from a loss of $1.1 million in the previous year [6][15] Financial Performance - Total revenue for the first quarter was $67.5 million, with MedTech revenue at $28 million (up 8.7% year-over-year) and Med Device revenue at $39.5 million (up 3.6% year-over-year) [18][19] - Adjusted EPS was a loss of $0.11 per share, improving from a loss of $0.16 per share in the same quarter last year [16][23] - Gross margin for the first quarter was 54.4%, slightly down from the previous year, but ahead of expectations [22] Product Performance - Auryon generated $13.7 million in revenue, growing 24.9% year-over-year, while AlphaVac contributed significantly to revenue growth [19][30] - AngioVac revenue was $2.2 million, marking a 21.1% increase year-over-year, attributed to the adoption of AlphaVac for pulmonary embolism treatment [19][20] - NanoKnife revenue declined 4.6% in disposable sales, with capital sales down 15%, primarily due to tough year-over-year comparisons [20][21] Strategic Initiatives - The company is transitioning to outsourced manufacturing, expected to generate approximately $15 million in annualized savings by fiscal 2027 [16][24] - AngioDynamics is pursuing new product launches and geographic expansions, with a total addressable market for MedTech now estimated at $10 billion, up from $3 billion three years ago [29][30] - The company is focused on increasing penetration in hospitals for Auryon and expanding its presence in the European market following CE mark approval [8][30] Guidance and Outlook - For fiscal year 2025, AngioDynamics expects revenue in the range of $282 million to $288 million, representing growth of 4.2% to 6.4% over fiscal year 2024 [27] - The company anticipates MedTech net sales growth of 10% to 12% and Med Device net sales growth of 1% to 3% [28] - AngioDynamics remains optimistic about achieving cash flow positivity by the end of fiscal year 2026, with expectations for reduced cash utilization in subsequent quarters [53][56]

Core Insights - The company reported strong financial performance in the second quarter of Fiscal 2026, with revenue growth of 8.8% to $79.4 million, driven by a 13% increase in the Med Tech segment and a 5.6% increase in the Med Device segment [2][12][23] - The company is raising its full-year guidance for revenue and adjusted EBITDA based on strong second-quarter results, now expecting net sales between $312 million and $314 million, representing growth of 6.6% to 7.3% over the previous fiscal year [22][23][24] - The company achieved significant regulatory milestones in its mechanical thrombectomy portfolio, which is expected to enhance its competitive position and expand clinical applications [4][6][7] Financial Performance - Adjusted EBITDA nearly doubled year-over-year, reaching $5.9 million compared to $3.1 million in the same quarter last year [2][21] - Gross margin improved to 56.4%, a 170 basis point increase from the previous year, driven by a favorable product mix and manufacturing optimization initiatives [18][19] - The company generated $4.7 million in cash during the quarter, exceeding expectations, and anticipates being cash flow positive for the full fiscal year [22][21] Business Segments - The Med Tech segment, which includes the Auryon platform, contributed $35.7 million in revenue, marking a 13% increase, with Auryon achieving 18 consecutive quarters of double-digit growth [12][13] - The mechanical thrombectomy portfolio, including AngioVac and AlphaVac, saw a combined revenue increase of 3.9% year-over-year, with AlphaVac revenue growing by 40.2% [14][15] - NanoKnife revenue reached $7.3 million, a 22.2% increase, driven by strong demand for prostate procedures following the recent implementation of a new CPT code [9][16] Regulatory and Market Developments - The company received IDE approvals for pivotal trials related to the AlphaReturn Blood Management System and AngioVac, which are expected to facilitate growth in their respective markets [6][7][39] - The recent CE Mark approval for Auryon is anticipated to enhance international sales, with ongoing efforts to expand into coronary applications [4][48][50] - The company is focused on increasing its market share in the atherectomy market, particularly in hospital settings, which has been a key driver of growth [13][14] Leadership Transition - The CEO announced plans to retire after a decade with the company, with a search committee established to find a successor [28][30] - The leadership transition is expected to be seamless, with the outgoing CEO continuing to oversee strategic initiatives until a new CEO is appointed [30][31]

Key Points The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business appears to be improving. 10 stocks we like better than AngioDynamics › Shares of AngioDynamics (NASDAQ: ANGO) were sinking 13.1% as of 11:02 a.m. ET. The sell-off came after the medical technology company announced its third-quarter results before the market open. Those results were actually q ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]